Moderna SEC filings, summarized
We read every Moderna 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track MRNA in your inbox
Add Moderna to your watchlist — free, every morning.
Recent filings
BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering…
BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering Spikevax & infectious disease vaccine pipeline,…
Moderna filed a Form 8‑K on Feb 13, 2026 furnishing a press release (Exhibit 99.1).
Moderna filed a Form 8‑K on Feb 13, 2026 furnishing a press release (Exhibit 99.1). Investors should review the release for any material updates. 📰 $MRNA…
Moderna ($MRNA) announced Q4 2025 financial results on Feb 13, 2026 for the quarter ended Dec 31, 2025 —…
Moderna ($MRNA) announced Q4 2025 financial results on Feb 13, 2026 for the quarter ended Dec 31, 2025 — press release furnished as Exhibit 99.1. 📄📈…
Moderna ($MRNA) filed an 8‑K (Item 9.01) on Feb 10, 2026 — Exhibit 99.1: press release dated Feb 10, 2026;…
Moderna ($MRNA) filed an 8‑K (Item 9.01) on Feb 10, 2026 — Exhibit 99.1: press release dated Feb 10, 2026; Exhibit 104: Inline XBRL cover page. Check…
FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will…
FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will not initiate review. Notice dated Feb 3, 2026;…
Moderna ($MRNA) said on Feb 10, 2026 it received a Refusal-to-File letter from the FDA for its…
Moderna ($MRNA) said on Feb 10, 2026 it received a Refusal-to-File letter from the FDA for its investigational seasonal influenza vaccine mRNA-1010. Press…
Moderna filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibits: 99.1 press release (dated Jan 12, 2026) and…
Moderna filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibits: 99.1 press release (dated Jan 12, 2026) and 104 Cover Page Inline XBRL. Signed by CFO James M.…
Moderna filed a Current Report on Form 8‑K (2026‑01‑12): Item 7.01 incorporates Item 2.02 and Exhibit 99.1…
Moderna filed a Current Report on Form 8‑K (2026‑01‑12): Item 7.01 incorporates Item 2.02 and Exhibit 99.1 — Regulation FD disclosure was furnished, not…
Moderna ($MRNA) preliminary FY2025: revenue ≈ $1.9B; GAAP operating expenses $5.0–$5.2B; cash, cash…
Moderna ($MRNA) preliminary FY2025: revenue ≈ $1.9B; GAAP operating expenses $5.0–$5.2B; cash, cash equivalents & marketable securities ≈ $8.1B. Press…
Moderna ($MRNA) filed Form 8-K (Item 9.01) on Jan 5, 2026 — Exhibit 99.1 is a shareholder letter dated Jan…
Moderna ($MRNA) filed Form 8-K (Item 9.01) on Jan 5, 2026 — Exhibit 99.1 is a shareholder letter dated Jan 5, 2026. Filing signed by Chief Legal Officer…
Moderna ($MRNA) issued a shareholder letter dated Jan 5, 2026; the letter is attached as Exhibit 99.1 and…
Moderna ($MRNA) issued a shareholder letter dated Jan 5, 2026; the letter is attached as Exhibit 99.1 and disclosed under Regulation FD. 📣📝 #RegulationFD…